Status:
UNKNOWN
COVID-19-Study of Immune Responses Following Vaccination Against SARS-CoV-2
Lead Sponsor:
Centre Hospitalier Universitaire de Besancon
Conditions:
Cancer
Elderly
Eligibility:
All Genders
18+ years
Brief Summary
T-cell adaptive immunity is known to be required to sustain a long term immunoglobulin production and a long term memory against several infections. Previous results suggest a lack in the generation o...
Eligibility Criteria
Inclusion
- \*
- Male or female patients
- Age ≥ 18 years
- Not having developed a symptomatic form of COVID-19 within the last 3 months before inclusion
- Eligible to the vaccination against SARS-CoV-2
- Affiliation to French social security or receiving such a regime,
- Signed informed consent
- Ability to comply with the study protocol, in the Investigator's judgment
- Cancer patients
- Patients under active anticancer treatment: in adjuvant or neoadjuvant setting or in first line of treatment in metastatic setting. Except for prostate cancer (until metastatic castration-resistant prostate cancer); and breast cancer hormonal receptor positive/HER2 negative (until apparition of hormonal resistance).
- Patients in follow-up (active treatment \< 3 months).
- Elderly:
- Age ≥ 70 years old
- Healthy person:
- Age ≥ 18 years old and \< 70 years old
- \*
Exclusion
- Patient under guardianship, guardianship or under the protection of justice
- Receipt of a live, attenuated vaccine within 4 weeks prior to the initiation of treatment or anticipation that such a live, attenuated vaccine will be required during the study.
Key Trial Info
Start Date :
April 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 25 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04836793
Start Date
April 15 2021
End Date
March 25 2023
Last Update
June 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Marie KROEMER
Besançon, France, 25000